Profiling of histone H3 lysine 9 trimethylation levels predicts transcription factor activity and survival in acute myeloid leukemia.
Standard
Profiling of histone H3 lysine 9 trimethylation levels predicts transcription factor activity and survival in acute myeloid leukemia. / Müller-Tidow, Carsten; Klein, Hans-Ulrich; Hascher, Antje; Isken, Fabienne; Tickenbrock, Lara; Thoennissen, Nils; Agrawal-Singh, Shuchi; Tschanter, Petra; Disselhoff, Christine; Wang, Yipeng; Becker, Anke; Thiede, Christian; Ehninger, Gerhard; Zur Stadt, Udo; Koschmieder, Steffen; Seidl, Matthias; Müller, Frank U; Schmitz, Wilhelm; Schlenke, Peter; McClelland, Michael; Berdel, Wolfgang E; Dugas, Martin; Serve, Hubert; Leukemia, Study Alliance.
In: BLOOD, Vol. 116, No. 18, 18, 2010, p. 3564-3571.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Profiling of histone H3 lysine 9 trimethylation levels predicts transcription factor activity and survival in acute myeloid leukemia.
AU - Müller-Tidow, Carsten
AU - Klein, Hans-Ulrich
AU - Hascher, Antje
AU - Isken, Fabienne
AU - Tickenbrock, Lara
AU - Thoennissen, Nils
AU - Agrawal-Singh, Shuchi
AU - Tschanter, Petra
AU - Disselhoff, Christine
AU - Wang, Yipeng
AU - Becker, Anke
AU - Thiede, Christian
AU - Ehninger, Gerhard
AU - Zur Stadt, Udo
AU - Koschmieder, Steffen
AU - Seidl, Matthias
AU - Müller, Frank U
AU - Schmitz, Wilhelm
AU - Schlenke, Peter
AU - McClelland, Michael
AU - Berdel, Wolfgang E
AU - Dugas, Martin
AU - Serve, Hubert
AU - Leukemia, Study Alliance
PY - 2010
Y1 - 2010
N2 - Acute myeloid leukemia (AML) is commonly associated with alterations in transcription factors because of altered expression or gene mutations. These changes might induce leukemia-specific patterns of histone modifications. We used chromatin-immunoprecipitation on microarray to analyze histone 3 lysine 9 trimethylation (H3K9me3) patterns in primary AML (n = 108), acute lymphoid leukemia (n = 28), CD34(+) cells (n = 21) and white blood cells (n = 15) specimens. Hundreds of promoter regions in AML showed significant alterations in H3K9me3 levels. H3K9me3 deregulation in AML occurred preferentially as a decrease in H3K9me3 levels at core promoter regions. The altered genomic regions showed an overrepresentation of cis-binding sites for ETS and cyclic adenosine monophosphate response elements (CREs) for transcription factors of the CREB/CREM/ATF1 family. The decrease in H3K9me3 levels at CREs was associated with increased CRE-driven promoter activity in AML blasts in vivo. AML-specific H3K9me3 patterns were not associated with known cytogenetic abnormalities. But a signature derived from H3K9me3 patterns predicted event-free survival in AML patients. When the H3K9me3 signature was combined with established clinical prognostic markers, it outperformed prognosis prediction based on clinical parameters alone. These findings demonstrate widespread changes of H3K9me3 levels at gene promoters in AML. Signatures of histone modification patterns are associated with patient prognosis in AML.
AB - Acute myeloid leukemia (AML) is commonly associated with alterations in transcription factors because of altered expression or gene mutations. These changes might induce leukemia-specific patterns of histone modifications. We used chromatin-immunoprecipitation on microarray to analyze histone 3 lysine 9 trimethylation (H3K9me3) patterns in primary AML (n = 108), acute lymphoid leukemia (n = 28), CD34(+) cells (n = 21) and white blood cells (n = 15) specimens. Hundreds of promoter regions in AML showed significant alterations in H3K9me3 levels. H3K9me3 deregulation in AML occurred preferentially as a decrease in H3K9me3 levels at core promoter regions. The altered genomic regions showed an overrepresentation of cis-binding sites for ETS and cyclic adenosine monophosphate response elements (CREs) for transcription factors of the CREB/CREM/ATF1 family. The decrease in H3K9me3 levels at CREs was associated with increased CRE-driven promoter activity in AML blasts in vivo. AML-specific H3K9me3 patterns were not associated with known cytogenetic abnormalities. But a signature derived from H3K9me3 patterns predicted event-free survival in AML patients. When the H3K9me3 signature was combined with established clinical prognostic markers, it outperformed prognosis prediction based on clinical parameters alone. These findings demonstrate widespread changes of H3K9me3 levels at gene promoters in AML. Signatures of histone modification patterns are associated with patient prognosis in AML.
KW - Humans
KW - Male
KW - Female
KW - Adolescent
KW - Child
KW - Prognosis
KW - Disease-Free Survival
KW - Child, Preschool
KW - Infant
KW - Promoter Regions, Genetic
KW - Antigens, CD34 immunology
KW - Gene Expression Regulation, Leukemic
KW - Hematopoietic Stem Cells immunology
KW - Histones genetics
KW - Leukemia, Myeloid, Acute diagnosis
KW - Lysine metabolism
KW - Methylation
KW - Protein Binding
KW - Transcription Factors metabolism
KW - Tumor Cells, Cultured
KW - Humans
KW - Male
KW - Female
KW - Adolescent
KW - Child
KW - Prognosis
KW - Disease-Free Survival
KW - Child, Preschool
KW - Infant
KW - Promoter Regions, Genetic
KW - Antigens, CD34 immunology
KW - Gene Expression Regulation, Leukemic
KW - Hematopoietic Stem Cells immunology
KW - Histones genetics
KW - Leukemia, Myeloid, Acute diagnosis
KW - Lysine metabolism
KW - Methylation
KW - Protein Binding
KW - Transcription Factors metabolism
KW - Tumor Cells, Cultured
M3 - SCORING: Zeitschriftenaufsatz
VL - 116
SP - 3564
EP - 3571
JO - BLOOD
JF - BLOOD
SN - 0006-4971
IS - 18
M1 - 18
ER -
